Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lupin Limited ( (IN:LUPIN) ) has issued an announcement.
Lupin Limited announced key decisions following a recent board meeting, including the reappointment of CEO Vinita Gupta and Executive Director Ramesh Swaminathan for five more years. The company also plans to transfer its OTC Consumer Healthcare Business to a new wholly owned subsidiary, along with the approval of an employee stock option scheme, which could impact its operational structure and employee engagement strategy.
More about Lupin Limited
Lupin Limited is a prominent pharmaceutical company specializing in the development and distribution of a range of pharmaceutical products. It focuses on both generic and branded formulations, with a significant presence in the global healthcare market.
YTD Price Performance: -8.25%
Average Trading Volume: 19,249
Current Market Cap: 1004.1B INR
Find detailed analytics on LUPIN stock on TipRanks’ Stock Analysis page.